FY2025 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Zacks Research decreased their FY2025 earnings per share estimates for shares of Bruker in a report released on Tuesday, October 15th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $3.04 for the year, down from their previous estimate of $3.07. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.95 EPS and FY2026 earnings at $3.63 EPS.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.52. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The company had revenue of $800.70 million for the quarter, compared to the consensus estimate of $799.44 million. During the same quarter in the prior year, the company earned $0.50 earnings per share. Bruker’s revenue was up 17.4% on a year-over-year basis.

Several other research analysts also recently weighed in on BRKR. Barclays assumed coverage on shares of Bruker in a research report on Tuesday. They issued an “overweight” rating and a $75.00 price target on the stock. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Citigroup cut their price target on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. Wells Fargo & Company began coverage on shares of Bruker in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price objective for the company. Finally, The Goldman Sachs Group cut their target price on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.82.

Bruker Stock Performance

BRKR opened at $60.49 on Wednesday. The company’s 50 day moving average is $65.09 and its 200 day moving average is $69.37. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The company has a market cap of $8.79 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 2.52 and a beta of 1.18. Bruker has a 12-month low of $53.79 and a 12-month high of $94.86.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.33%. Bruker’s dividend payout ratio (DPR) is 7.27%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP lifted its holdings in shares of Bruker by 127.8% in the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after acquiring an additional 779,549 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Bruker in the 2nd quarter valued at approximately $36,472,000. AQR Capital Management LLC lifted its stake in shares of Bruker by 123.6% in the 2nd quarter. AQR Capital Management LLC now owns 555,468 shares of the medical research company’s stock valued at $35,444,000 after purchasing an additional 307,021 shares during the last quarter. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of Bruker by 78.3% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 593,091 shares of the medical research company’s stock worth $37,845,000 after purchasing an additional 260,363 shares during the period. Finally, Point72 Europe London LLP increased its position in shares of Bruker by 262.9% during the 2nd quarter. Point72 Europe London LLP now owns 333,997 shares of the medical research company’s stock valued at $21,312,000 after purchasing an additional 241,959 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.